不同剂量生长激素在青春期前儿童的应用对生长速率及骨龄进展分析  

Analysis of Growth Rate and Bone Age Progression in Prepubertal Children with Different Doses of Growth Hormone

作　　者：曾橹炜 朱黄羽 郑翔蓉 杨美环 吴春斌 陈鹤 ZENG Luwei;ZHU Huangyu;ZHENG Xiangrong;YANG Meihuan;WU Chunbin;CHEN He(Department of Pediatrics,Xianyou General Hospital,Putian 351200,China)

机构地区：[1]仙游县总医院儿科,莆田351200

出　　处：《中国医药指南》2024年第29期13-16,共4页Guide of China Medicine

基　　金：莆田市科技计划项目(莆市科(2022)33号)。

摘　　要：目的分析矮小症小儿在青春期前应用不同剂量的生长激素对患儿生长速率与骨龄生长速度的影响。方法基于纳排标准筛取我院2022年6月至2022年12月期间收治的80例青春期前矮小症小儿为观察对象,依据数字列表法随机均分三组,进行常规治疗的20例小儿为对照组,联合高剂量重组人生长激素的30例小儿为高剂量组,联合低剂量的30例小儿为低剂量组,对照三组小儿的发育信息以及药物不良反应发生率。结果在治疗前,三组患儿的骨龄(BA)、身高、BA/生活年龄(CA)、生长速率(GR)、身高均值标准差积分(HtSDS)、成年身高预测(PAH)表达均无统计学差异(P>0.05),在治疗后的6、12、18个月,三组患儿的BA、身高、HtSDS、PAH、GR均升高(均P<0.05)。在治疗后的6、12、18个月高剂量组小儿的身高、HtSDS、PAH、GR表达高于低剂量组,高于对照组,且低剂量组高于对照组(均P<0.05)。三组患儿药物不良反应发生率对比差异统计学意义(P>0.05)。结论矮小症小儿在青春期前应用高剂量生长激素相较于低剂量可更为显著的提升患儿生长速率,且不会明显增加骨龄发育,安全性较佳。Objective To analyze the effects of different doses of growth hormone on the growth rate and bone age of children with nanosomia before puberty.Methods Eighty children with preadolescent nanosomia treated in our hospital from June 2022 to December 2022 were selected as observation objects based on the exclusion criteria,and randomly divided into 3 groups according to the numerical tabulation method.20 children receiving conventional treatment were selected as control group,30 children receiving combined high-dose recombinant human growth hormone were selected as high-dose group,and 30 children receiving combined low-dose human growth hormone were selected as low-dose group.Compare the developmental information(elevation,weight,bone age,development ratio,adult height prediction)and incidence of adverse drug reactions among three groups of children.Results Before treatment,there were no statistically significant differences in bone age(BA),height,BA/life age(CA),growth rate(GR),height mean standard deviation score(HtSDS),and prediction of adult height(PAH)expression among the three groups of children(P>0.05).At 6,12,and 18 months after treatment,BA,height,HtSDS,PAH,and GR were elevated in all three groups(all P<0.05).At 6,12 and 18 months after treatment the height,HtSDS,PAH and GR expression of the children in the high dose group was higher than that of the low dose group and the control group,and higher in the low-dose group than in the control group(all P<0.05).Comparison of the incidence of adverse drug reactions among children in the three groups is statistically significant(P>0.05).Conclusions Compared with low dose,high dose of growth hormone before puberty can significantly increase the growth rate of children with nanosomia,and does not significantly increase bone age and development,and has good safety.

关 键 词：矮小症 重组人生长激素 青春期前 高剂量 生长速率 骨龄 

分 类 号：R179[医药卫生—妇幼卫生保健] R725.8[医药卫生—公共卫生与预防医学]